RU98105689A - ALPHA TUMOR NECROSIS FACTOR INHIBITORS - Google Patents
ALPHA TUMOR NECROSIS FACTOR INHIBITORSInfo
- Publication number
- RU98105689A RU98105689A RU98105689/04A RU98105689A RU98105689A RU 98105689 A RU98105689 A RU 98105689A RU 98105689/04 A RU98105689/04 A RU 98105689/04A RU 98105689 A RU98105689 A RU 98105689A RU 98105689 A RU98105689 A RU 98105689A
- Authority
- RU
- Russia
- Prior art keywords
- carbon atoms
- substituted
- alkyl
- amino
- carbamoyl
- Prior art date
Links
- 229940046728 Tumor necrosis factor alpha (TNF-) inhibitors Drugs 0.000 title 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 title 1
- 125000004432 carbon atoms Chemical group C* 0.000 claims 22
- -1 carbethoxy, carbomethoxy, carbopropoxy, acetyl Chemical group 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 2
- 101710031992 pRL90232 Proteins 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 101710035540 plaa2 Proteins 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 2
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 125000004429 atoms Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 1
Claims (1)
где Y представляет
m равно 0-3;
R5 представляет: (i) о-фенилен, незамещенный или замещенный одним или несколькими заместителями, каждый из которых, независимо выбран из нитро, циано, трифторметила, карбэтокси, карбометокси, карбопропокси, ацетила, карбамоила, карбамоила, замещенного алкилом с 1-3 атомами углерода, ацетокси, карбокси, гидрокси, амино, амино, замещенной алкилом с 1-3 атомами углерода, алкилом с 1-4 атомами углерода, алкокси с 1-4 атомами углерода или галогеном; (ii) двухвалентный остаток пиридина, пирролидина, имидизола, нафталина или тиофена, где двухвалентные связи находятся у смежных атомах углерода в кольце; (iii) двухвалентный циклоалкил с 4-10 атомами углерода, незамещенный или замещенный одним или несколькими заместителями, каждый из которых независимо выбран из группы, включающей нитро, циано, трифторметил, карбэтокси, карбометокси, карбопропокси, ацетил, карбамоил, ацетокси, карбокси, гидрокси, амино, замещенную амино, алкил с 1-10 атомами углерода, алкокси с 1-10 атомами углерода, фенил или галоген; (iv) ди-замещенный винилен, замещенный нитро, циано, трифторметилом, карбэтокси, карбометокси, карбопропокси, ацетилом, карбамоилом, карбамоилом, замещенным алкилом с 1-3 атомами углерода, ацетокси, карбокси, гидрокси, амино, амино, замещенную алкилом с 1-3 атомами углерода, алкилом с 1-4 атомами углерода, алкокси с 1-4 атомами углерода, или галогеном; или (v) этилен, незамещенный или замещенный 1-2 заместителями, каждый из которых независимо выбран из нитро, циано, трифторметила, карбэтокси, карбометокси, карбопропокси, ацетила, карбамоила, карбамоила, замещенного алкилом с 1-3 атомами углерода, ацетокси, карбокси, гидрокси, амино, амино, замещенной алкилом с 1-3 атомами углерода, алкилом с 1-4 атомами углерода, алкокси с 1-4 атомами углерода или галогеном;
R6 представляет -СО-, -СН2-, -СН2СО- или -SO2;
R7 представляет (i) неразветвленный или разветвленный алкил с 1-12 атомами углерода; (ii) циклический или бициклический алкил с 4-12 атомами углерода; (iii) пиридил; (iv) фенил, замещенный одним или несколькими заместителями, каждый из которых независимо выбран из нитро, циано, трифторметила, карбэтокси, карбометокси, карбопропокси, ацетила, карбамоила, ацетокси, карбокси, гидрокси, амино, неразветвленного, разветвленного, циклического или бициклического алкила с 1-10 атомами углерода, неразветвленного, разветвленного, циклического или бициклического алкокси с 1-10 атомами углерода, CH2R, где R является циклическим или бициклическим алкилом с 1-10 атомами углерода или галогеном; (v) бензил, замещенный одним или тремя заместителями, каждый из которых независимо выбран из группы, включающей нитро, циано, трифторметил, карбэтокси, карбометокси, карбопропокси, ацетил, карбамоил, ацетокси, карбокси, гидрокси, амино, алкил с 1-4 атомами углерода, алкокси с 1-10 атомами углерода или галоген; (vi) нафтил; или (vii) бензилокси; и где n имеет значение 0, 1, 2 или 3.1. The composition having the formula:
where Y represents
m is 0-3;
R 5 represents: (i) o-phenylene unsubstituted or substituted by one or more substituents, each of which is independently selected from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, carbamoyl, substituted with alkyl from 1-3 carbon atoms, acetoxy, carboxy, hydroxy, amino, amino, substituted by alkyl with 1-3 carbon atoms, alkyl with 1-4 carbon atoms, alkoxy with 1-4 carbon atoms or halogen; (ii) a divalent residue of pyridine, pyrrolidine, imidizole, naphthalene or thiophene, where the divalent bonds are located on adjacent carbon atoms in the ring; (iii) divalent cycloalkyl with 4-10 carbon atoms, unsubstituted or substituted by one or more substituents, each of which is independently selected from the group consisting of nitro, cyano, trifluoromethyl, carbetoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy , amino, substituted amino, alkyl with 1-10 carbon atoms, alkoxy with 1-10 carbon atoms, phenyl or halogen; (iv) di-substituted vinylene substituted with nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, carbamoyl substituted with alkyl of 1-3 carbon atoms, acetoxy, carboxy, hydroxy, amino, amino, substituted with 1 -3 carbon atoms, alkyl with 1-4 carbon atoms, alkoxy with 1-4 carbon atoms, or halogen; or (v) ethylene, unsubstituted or substituted by 1-2 substituents, each independently selected from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, carbamoyl, substituted by alkyl with 1-3 carbon atoms, acetoxy, carboxy , hydroxy, amino, amino, substituted by alkyl with 1-3 carbon atoms, alkyl with 1-4 carbon atoms, alkoxy with 1-4 carbon atoms or halogen;
R 6 is —CO—, —CH 2 -, —CH 2 CO— or —SO 2 ;
R 7 represents (i) unbranched or branched alkyl with 1-12 carbon atoms; (ii) cyclic or bicyclic alkyl with 4-12 carbon atoms; (iii) pyridyl; (iv) phenyl substituted with one or more substituents, each independently selected from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, unbranched, branched, cyclic or bicyclic alkyl with 1-10 carbon atoms, unbranched, branched, cyclic or bicyclic alkoxy with 1-10 carbon atoms, CH 2 R, where R is cyclic or bicyclic alkyl with 1-10 carbon atoms or halogen; (v) benzyl substituted with one or three substituents, each independently selected from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl with 1-4 atoms carbon, alkoxy with 1-10 carbon atoms or halogen; (vi) naphthyl; or (vii) benzyloxy; and where n is 0, 1, 2 or 3.
4. Способ ингибирования фосфодиэстеразы у млекопитающего, который включает введение ему эффективного количества соединения по п.1.3. A pharmaceutical composition comprising an amount of a compound according to claim 1, effective in a single or multiple dose, for inhibiting FHOα.
4. A method of inhibiting phosphodiesterase in a mammal, which comprises administering to it an effective amount of a compound according to claim 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/520,710 US5728845A (en) | 1995-08-29 | 1995-08-29 | Immunotherapeutic nitriles |
| US08/520,710 | 1995-08-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU98105689A true RU98105689A (en) | 2000-02-10 |
| RU2196134C2 RU2196134C2 (en) | 2003-01-10 |
Family
ID=24073769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU98105689/04A RU2196134C2 (en) | 1995-08-29 | 1996-08-29 | Substituted amides, method of decrease of tumor necrosis factor (tnf) level and inhibition of phosphodiesterase activity and pharmaceutical composition |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US5728845A (en) |
| EP (3) | EP1367051A3 (en) |
| JP (2) | JP2000500118A (en) |
| KR (2) | KR20030097902A (en) |
| AT (1) | ATE259787T1 (en) |
| AU (1) | AU716775B2 (en) |
| CA (1) | CA2230487A1 (en) |
| CZ (1) | CZ291613B6 (en) |
| DE (1) | DE69631592T2 (en) |
| DK (1) | DK0851857T3 (en) |
| ES (1) | ES2216059T3 (en) |
| FI (1) | FI980038A (en) |
| HK (1) | HK1022692A1 (en) |
| HU (1) | HUP9901410A3 (en) |
| NZ (1) | NZ318212A (en) |
| PL (1) | PL329107A1 (en) |
| PT (1) | PT851857E (en) |
| RU (1) | RU2196134C2 (en) |
| SK (1) | SK284144B6 (en) |
| WO (1) | WO1997008143A1 (en) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| US5703098A (en) * | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
| US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
| US5728844A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
| US6518281B2 (en) * | 1995-08-29 | 2003-02-11 | Celgene Corporation | Immunotherapeutic agents |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| CA2262906C (en) * | 1996-08-12 | 2006-10-31 | Celgene Corporation | Novel immunotherapeutic agents and their use in the reduction of cytokine levels |
| US6140827A (en) * | 1997-12-18 | 2000-10-31 | Micron Technology, Inc. | Method and apparatus for testing bumped die |
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| TR200201317T2 (en) | 1999-08-21 | 2002-11-21 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Synergistic combination. |
| US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| US7182953B2 (en) * | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| US6699899B1 (en) | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
| US6326388B1 (en) * | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
| WO2001068600A2 (en) * | 2000-03-16 | 2001-09-20 | Inflazyme Pharmaceuticals Limited | Benzylated pde4 inhibitors |
| US8030343B2 (en) * | 2000-06-08 | 2011-10-04 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US7491634B2 (en) * | 2006-04-28 | 2009-02-17 | Asm International N.V. | Methods for forming roughened surfaces and applications thereof |
| WO2002081447A1 (en) * | 2001-04-06 | 2002-10-17 | Daewoong Pharmaceutical Co., Ltd. | 3-cyclopentyloxy-4-methoxyphenyl-isothiazolinone derivatives and the use thereof |
| WO2002081446A1 (en) * | 2001-04-06 | 2002-10-17 | Daewoong Co., Ltd. | 3-cyclopentyloxy-4-methoxyphenyl-isoindolinone derivatives and the use thereof |
| AU2002303265A1 (en) * | 2001-04-10 | 2002-10-28 | Message Pharmaceuticals, Inc. | Small molecule inhibitors of secretion of proteins encoded by are-mrnas |
| US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| US7276529B2 (en) * | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
| US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| US7208516B2 (en) * | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
| US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| CA2481385A1 (en) * | 2002-04-12 | 2003-10-23 | Celgene Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| EP1496878A4 (en) * | 2002-04-12 | 2007-12-26 | Celgene Corp | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds |
| CA2486141A1 (en) | 2002-05-17 | 2003-11-27 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
| EP1551385A4 (en) * | 2002-10-15 | 2008-10-22 | Celgene Corp | Selective cytokine inhibitory drugs for treating myelodysplastic syndrome |
| US20040087558A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| US7776907B2 (en) * | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
| JP2006508131A (en) | 2002-11-06 | 2006-03-09 | セルジーン・コーポレーション | Methods and compositions using selective cytokine inhibitors for the treatment and management of cancer and other diseases |
| ZA200503653B (en) * | 2002-11-06 | 2006-08-30 | Celgene Corp | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
| CA2506442A1 (en) * | 2002-11-18 | 2004-07-01 | Celgene Corporation | Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
| BR0316259A (en) * | 2002-11-18 | 2005-10-04 | Celgene Corp | Methods of inhibiting TNF-alpha production and pde4 activity, treating or preventing a disease or disorder, controlling camp levels in a cell, and producing a compound, pharmaceutical composition and compound |
| CN1802353A (en) | 2002-12-30 | 2006-07-12 | 细胞基因公司 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses |
| JP2006519875A (en) * | 2003-03-06 | 2006-08-31 | セルジーン・コーポレーション | Selective cytokine inhibitors for treating central nervous system disorders |
| US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| US20050187278A1 (en) * | 2003-08-28 | 2005-08-25 | Pharmacia Corporation | Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors |
| US20050142104A1 (en) * | 2003-11-06 | 2005-06-30 | Zeldis Jerome B. | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders |
| JP2007511618A (en) | 2003-11-19 | 2007-05-10 | シグナル ファーマシューティカルズ，エルエルシー | Indazole compounds and methods of use as protein kinase inhibitors |
| EP1744748A4 (en) * | 2004-04-14 | 2009-08-12 | Celgene Corp | Method of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myelodysplastic syndromes |
| MXPA06012279A (en) * | 2004-04-23 | 2007-01-31 | Celgene Corp | Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension. |
| US7244759B2 (en) * | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
| US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| ZA200702380B (en) | 2004-09-03 | 2008-09-25 | Celgene Corp | Substituted heterocyclic compounds and uses thereof |
| MX2007005040A (en) * | 2004-10-28 | 2007-06-19 | Celgene Corp | Methods and compositions using pde4 modulators for treatment and management of central nervous system injury. |
| US7582629B2 (en) | 2005-01-10 | 2009-09-01 | Astrazeneca Ab | Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators |
| SE0500055D0 (en) | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 3 |
| US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
| US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
| CA2718412A1 (en) * | 2008-03-24 | 2009-10-01 | Celgene Corporation | Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
| MY160002A (en) | 2009-02-10 | 2017-02-15 | Celgene Corp | Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis |
| JP5937060B2 (en) | 2010-04-07 | 2016-06-22 | セルジーン コーポレイション | Method for treating respiratory viral infections |
| JP2013531499A (en) | 2010-06-15 | 2013-08-08 | セルジーン コーポレイション | Biomarkers for the treatment of psoriasis |
| US9087349B2 (en) | 2012-12-27 | 2015-07-21 | Panasonic Intellectual Property Corporation Of America | Information communication method |
| EP3142663A1 (en) | 2014-05-16 | 2017-03-22 | Celgene Corporation | Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators |
| ES2749433T3 (en) | 2014-06-23 | 2020-03-20 | Celgene Corp | Apremilast for the treatment of liver disease or abnormal liver function |
| US10682336B2 (en) | 2015-10-21 | 2020-06-16 | Amgen Inc. | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| CN111568794B (en) * | 2020-06-17 | 2021-05-18 | 上海交通大学 | New use of active ingredient WGX50 in fructus Zanthoxyli extract |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4173652A (en) | 1976-12-18 | 1979-11-06 | Akzona Incorporated | Pharmaceutical hydroxamic acid compositions and uses thereof |
| DE3242477A1 (en) * | 1982-11-18 | 1984-05-24 | Basf Ag, 6700 Ludwigshafen | HETEROCYCLICALLY SUBSTITUTED NITRILES, THEIR PRODUCTION AND USE AS MEDICINAL PRODUCTS |
| US4820828A (en) | 1987-03-04 | 1989-04-11 | Ortho Pharmaceutical Corporation | Cinnamohydroxamic acids |
| EP0308371A1 (en) * | 1987-09-18 | 1989-03-22 | Ciba-Geigy Ag | 4-Aza-saccharines, 4-aza-dihydro- or -tetrahydrosaccharines and process for their preparation |
| US5455353A (en) * | 1993-03-24 | 1995-10-03 | Hoffmann-La Roche Inc. | 4-(benzyl-2-oxo-oxazolidin-5 ylmethyl)N tertbutyl-decahydroisoquinoline-3-carboxamides |
| US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| ES2151156T3 (en) | 1995-07-26 | 2000-12-16 | Pfizer | ACID DERIVATIVES N- (AROIL) GLYCINE HYDROXAMICS AND RELATED COMPOUNDS. |
-
1995
- 1995-08-29 US US08/520,710 patent/US5728845A/en not_active Expired - Fee Related
-
1996
- 1996-08-29 CZ CZ1998609A patent/CZ291613B6/en not_active IP Right Cessation
- 1996-08-29 KR KR10-2003-7015515A patent/KR20030097902A/en not_active Application Discontinuation
- 1996-08-29 AU AU69632/96A patent/AU716775B2/en not_active Ceased
- 1996-08-29 EP EP03077311A patent/EP1367051A3/en not_active Withdrawn
- 1996-08-29 EP EP99200946A patent/EP0957091B1/en not_active Expired - Lifetime
- 1996-08-29 JP JP9510629A patent/JP2000500118A/en not_active Ceased
- 1996-08-29 DK DK96930664T patent/DK0851857T3/en active
- 1996-08-29 SK SK272-98A patent/SK284144B6/en unknown
- 1996-08-29 WO PCT/US1996/014077 patent/WO1997008143A1/en active IP Right Grant
- 1996-08-29 PL PL96329107A patent/PL329107A1/en unknown
- 1996-08-29 KR KR10-1998-0701029A patent/KR100440874B1/en not_active IP Right Cessation
- 1996-08-29 RU RU98105689/04A patent/RU2196134C2/en not_active IP Right Cessation
- 1996-08-29 CA CA002230487A patent/CA2230487A1/en not_active Abandoned
- 1996-08-29 DE DE69631592T patent/DE69631592T2/en not_active Expired - Fee Related
- 1996-08-29 EP EP96930664A patent/EP0851857B1/en not_active Expired - Lifetime
- 1996-08-29 HU HU9901410A patent/HUP9901410A3/en unknown
- 1996-08-29 AT AT96930664T patent/ATE259787T1/en not_active IP Right Cessation
- 1996-08-29 PT PT96930664T patent/PT851857E/en unknown
- 1996-08-29 NZ NZ318212A patent/NZ318212A/en unknown
- 1996-08-29 ES ES96930664T patent/ES2216059T3/en not_active Expired - Lifetime
-
1998
- 1998-01-09 FI FI980038A patent/FI980038A/en unknown
- 1998-01-14 US US09/007,135 patent/US5968945A/en not_active Expired - Lifetime
-
1999
- 1999-06-11 US US09/330,701 patent/US6180644B1/en not_active Expired - Lifetime
-
2000
- 2000-03-20 HK HK00101665A patent/HK1022692A1/en not_active IP Right Cessation
-
2008
- 2008-02-25 JP JP2008043383A patent/JP2008133303A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU98105689A (en) | ALPHA TUMOR NECROSIS FACTOR INHIBITORS | |
| RU97112857A (en) | NEW IMMUNOTHERAPEUTIC ARILAMIDES | |
| RU99113849A (en) | IMMUNOTHERAPEUTIC IMIDES / AMIDES AS A PDE IV INHIBITOR AND TNF | |
| RU97112858A (en) | SUBSTITUTED IMIDES AS INHIBITORS | |
| EA199801047A1 (en) | Mixed causal inlazole and their use as inhibitors of phosphodiesterrase (PDE) TYPE IV and the tumor necrosis factor (TNF) | |
| RU98108602A (en) | Succinimide and maleimide cytokine inhibitors | |
| EA199800882A1 (en) | Derivatives of Mixed Indazols, Their Use as Photophodiesterrase Inhibitors (PDE) IV and Obtaining Tumor Necrosis Factor (TNF) | |
| EA199900183A1 (en) | DERIVATIVES OF INDASOLS AND THEIR USE AS INHIBITORS OF PHOSPHODYSTERASE (PDE) TYPE IV AND PRODUCING OF THE TUMOR NECROSIS (TNF) FACTOR | |
| CA2208746A1 (en) | Novel immunotherapeutic aryl amides | |
| ES2172595T3 (en) | COMPOUNDS OF 1-ACIL-4-ALIFATILAMINOPIPERIDINA. | |
| RU99115766A (en) | BENZOTIOPHENCARBOXAMIDE DERIVATIVES CONTAINING THEIR PGD2 ANTAGONISTS PHARMACEUTICAL COMPOSITION AND MEDICINE | |
| EA200000637A1 (en) | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN-TYROSINKINAZ INHIBITORS | |
| EA199800541A1 (en) | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOUNDS, THEIR CONTAINING THEM, AND THEIR PHARMACEUTICAL APPLICATIONS, AND WAYS AND INTERMEDIATE CONNECTIONS, SUITABLE FOR THEM | |
| EA200100766A1 (en) | QUINOLIN-2-ON-SUBSTITUTED HETEROAARYNE DERIVATIVES USED AS ANTI-TUMOR AGENTS | |
| RU96111958A (en) | PHARMACEUTICAL COMPOSITION | |
| RU2003134153A (en) | DIPEPTIDES CONTAINING A 2-THIOACYL GROUP ON THE N-TERMINAL AMINO ACID RESIDUE, AS VASOPEPTIDASE INHIBITORS | |
| DE60220255T2 (en) | N-PHENYLARYLSULFONAMIDE COMPOUND, MEDICAMENT CONTAINING THIS COMPOUND AS AN ACTIVE SUBSTANCE, INTERMEDIATE PRODUCT FOR THE COMPOUND, AND METHOD FOR THE PRODUCTION THEREOF | |
| ES431307A1 (en) | Tetrahydro-azepinoquinolines | |
| EA199700160A1 (en) | INDOLA DERIVATIVES AS AN ANTAGONISTS EAA | |
| RU94036760A (en) | Triazine derivatives, their synthesis and use | |
| RU97115107A (en) | BICYCLIC DERIVATIVES OF ISOTHYOTURES USED IN THERAPY | |
| RU97112903A (en) | IMID / AMIDE ETHERS, PHARMACEUTICAL COMPOSITION ON THE BASIS AND METHOD FOR REDUCING THE MONOGRAPHY LEVEL (TNFA) IN MAMMALS | |
| EA200400770A1 (en) | DERIVATIVES 5- (PIRIDIN-3-IL) -1-AZABICYCLO [3.2.1] OKTANA, THEIR RECEIVING AND APPLICATION IN THERAPY | |
| RU99113432A (en) | NEW DERIVATIVES OF PHENANTRIDINIA | |
| ES8604958A1 (en) | Imidazoquinoline derivatives. |